Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Methylenetetrahydrofolate Reductase Polymorphism in the Etiology of Down Syndrome
- B. Chadefaux-Vekemans, M. Coudé, +4 authors P. Kamoun
- Biology, MedicinePediatric Research
- 1 June 2002
A cohort of 85 women carrying fetuses with Down syndrome is studied and there is no difference in the frequencies of the three groups of subjects between Down syndrome mothers and controls.
The fasting test in paediatrics: Application to the diagnosis of pathological hypo- and hyperketotic states
- J. Bonnefont, N. Specola, +7 authors J. Saudubray
- MedicineEuropean Journal of Pediatrics
- 1 December 1990
In children with a suspected or definite hyperketotic or hypoketotic disorder, a fasting test must only be performed in healthy patients, in good nutritional condition with non-diagnostic basal biochemical investigations.
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.
Dasatinib combined with low-intensity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph(+) ALL and monitoring of BCR-ABL1(T315I) from diagnosis identified patients with at high risk of early relapse and may help to personalize therapy.
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French…
- M. Balsat, Aline Renneville, +20 authors N. Boissel
- MedicineJournal of clinical oncology : official journal…
- 10 January 2017
This study supports the strong prognostic significance of early NPM1m PB-MRD, independent of the cytogenetic and molecular context, and addresses the question of whether N PM1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit.
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study
- C. Payan, F. Roudot-thoraval, +50 authors F. Lunel-Fabiani
- Biology, MedicineJournal of viral hepatitis
- 1 July 2005
A changing pattern of HCV genotypes in France is shown, with i.v. drug abuse as the major risk factor, an increase of genotype 4, and to a lesser extent 1a and 5, and a decrease of genotypes 1b and 2.
Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients.
- P. Chauveau, B. Chadefaux, +4 authors P. Jungers
- MedicineKidney international. Supplement
- 1 June 1993
Fasting plasma level of total, protein-bound Hcy was significantly higher in 20 patients (16 males) who had past histories of occlusive arterial disease than in the 59 (31 male) who did not (30.9 +/- 19.1 vs. 19.6 +/- 9.7 mumol/liter, P < 0.001); linear regression analysis showed a significant correlation between plasma creatinine and Hcy concentrations.
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
OtX015 and JQ1 have similar biological effects in leukemic cells, supporting OTX015 evaluation in a Phase Ib trial in relapsed/refractory leukemia patients and Sequential combinations of OTx015 with other epigenetic modifying drugs, panobinostat and azacitidine have a synergic effect on growth of the KASUMI cell line.
aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16.
- X. Montagutelli, A. Lalouette, M. Coudé, P. Kamoun, M. Forest, J. Guénet
- Biology, MedicineGenomics
A new recessive mutation (aku) is found in the mouse that is homologous to human alkaptonuria, during a mutagenesis program with ethylnitrosourea, in a region of synteny with human 3q.
Concentrations of total homocysteine in plasma in chronic renal failure.
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment in Patients with De Novo Philadelphia Positive ALL Aged 55 and Over: Final Results of the EWALL-Ph-01 Study
A study at the European level evaluating the combination of dasatinib and chemotherapy for Philadelphia positive (Ph+) ALL patients aged 55 and over to analyse efficacy of Dasatinib combined to low intensity chemotherapy and to test factors associated with outcome.